USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ENSION, INC.
Address:
240 WILLIAM PITT WAY
PITTSBURGH, PA 15238-1328
Phone:
N/A
URL:
N/A
EIN:
125179894
DUNS:
100758015
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,063,591.00 16
SBIR Phase II $6,192,093.00 6

Award List:

High Efficiency Dialyzer Development

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Mark J. Gartner
Abstract:
The goal of this project is develop a highly efficient active mixing hemodialyzer for patients in renal failure. We intend to replicate our active mixing membrane oxygenator (AMMO) technology currently under development to this device. Mass transfer in AMMO devices has proven to be 5-8 times more… More

Simplified Pump Oxygenator for Pediatric Use

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Philip Litwak
Abstract:
DESCRIPTION (Verbatim from the Applicant's Abstract): Cardiopulmonary Technologies, Inc. (CPT) has developed very efficient Active Mixing Membrane Oxygenator (AMMO) with an inherent ability to pump blood as it transfers gases. Currently, this device consists of 0.18 M2 of… More

SIMPLIFIED PUMP OXYGENATOR FOR PEDIATRIC USE PHASE II

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of the project is to develop new positive inotropes, represented by specifically modified AMP molecules. All of the currently available positive inotropic agents have significant adverse effects with digitalis being the only orally available positive… More

SIMPLIFIED PUMP OXYGENATOR FOR PEDIATRIC USE PHASE II

Award Year / Program / Phase:
2002 / SBIR / Phase II
Award Amount:
$1,177,557.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of the project is to develop new positive inotropes, represented by specifically modified AMP molecules. All of the currently available positive inotropic agents have significant adverse effects with digitalis being the only orally available positive… More

AMBULATORY ECMO SYSTEM

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$199,821.00
Agency:
HHS
Principal Investigator:
Abstract:
Ension, Inc. has developed a very efficient Active Mixing Membrane Oxygenator (AMMO) with an inherent ability to pump blood as it transfers gases. Currently, this device consists of 0.5 m2 of membrane surface area and pumps 6.0 Lpm of blood. Envsion is proposing to alter its current acute-use AMMO… More

PNEUMATICALLY ACTUATED INTEGRATED LIFE SUPPORT SYSTEM

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$198,467.00
Agency:
HHS
Principal Investigator:
Abstract:
Description (provided by applicant): Ension, Inc. has previously developed integrated blood pump-oxygenator technologies offering many advantages over current clinical systems. In particular, the small size of the integrated devices has been well received by our colleagues in the "MedEvac" field as… More

ACTIVE MIXING MEMBRANE OXYGENATOR PHASE II

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
Ension, Inc. and its development partner, the University of Pittsburgh, have developed and patented an active mixing membrane oxygenator (AMMO), which has been proven to be highly efficient in terms of oxygenation and decarbonation (5-8 times that of oxygenators currently in use), capable of pumping… More

ACTIVE MIXING MEMBRANE OXYGENATOR PHASE II

Award Year / Program / Phase:
2002 / SBIR / Phase II
Award Amount:
$749,976.00
Agency:
HHS
Principal Investigator:
Abstract:
Ension, Inc. and its development partner, the University of Pittsburgh, have developed and patented an active mixing membrane oxygenator (AMMO), which has been proven to be highly efficient in terms of oxygenation and decarbonation (5-8 times that of oxygenators currently in use), capable of pumping… More

Pulsatile Pediatric Blood Pump Development-Phase II

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$933,480.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Ension, Inc. is seeking to complete the development of a pulsatile pediatric blood pump, CardioFIowPQ, that is specifically designed for use in neonatal and small-sized pediatric patients, less than 10kg body weight. The Ension device supports beat rates up to… More

Left Atrial Appendage Isolation Device to Reduce Stroke

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$198,781.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cardiac dysarrhythmia, currently affecting over 2 million Americans. Embolic material from thrombus in the fibrillating left atrium (LA) has been documented as a major cause of stroke, especially in the elderly.… More

Real-time cardiopulmonary perfusion monitoring system

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$99,475.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Discrete arterial blood gas measurement (ABG) remains as the "gold standard" used by perfusionists to ascertain the effectiveness of their ability to maintain homeostasis during cardiopulmonary bypass. There are two major problems with this practice; ABG only… More

High Efficiency Dialyzer Development - Phase 2

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Hemodialysis is currently required by more than 200,000 Americans with this number expected to climb significantly in the next decade. During each dialysis session, only a portion of the waste products normally eliminated by the kidneys is actually removed.… More

High Efficiency Dialyzer Development - Phase 2

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$825,271.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Hemodialysis is currently required by more than 200,000 Americans with this number expected to climb significantly in the next decade. During each dialysis session, only a portion of the waste products normally eliminated by the kidneys is actually removed.… More

Fetal Perfusion System

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$95,820.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The diagnosis of certain congenital heart defects can now be made as early as 12 weeks of gestation due to advances in fetal echocardiography. Fetal cardiac surgery, which has been investigated since the early 1980s, is an increasingly viable solution to prevent… More

Perfusion System for In Utero Cardiac Surgery

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$928,315.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Due to advances in fetal echocardiography, fetal cardiac surgery is an increasingly viable strategy to prevent simple cardiac lesions from progressing into serious defects requiring multiple corrective surgeries after birth. A significant obstacle to successful… More

Endovascular surgery system for atrial septal defect repair

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$269,950.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Atrial septal defect (ASD) is one of the most common congenital heart defects found in pediatrics and adults. Surgical repair of ASD has been considered the gold standard for correction of ASD, however, to avoid complications associated with open-chest operation… More

Biocompatible Coating for Pediatric Blood Oxygenators

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$152,978.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Many oxygenators clinically available for adult and pediatric extracorporeal membrane oxygenation (ECMO) employ heparin coatings on microporous hollow fibers to improve biocompatibility. Despite application of these coatings, significant inflammatory and… More

Oxygen Permeable Membrane for Lithium Air Batteries

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$99,987.00
Agency / Branch:
DOD / OSD
Principal Investigator:
Greg Johnson, Principal Scientist
Abstract:
The objective of this proposal is to demonstrate the feasibility of producing an oxygen permeable membrane using plasma deposition of polymer films on a microporous substrate material. Membranes that are permeable to oxygen are needed to allow oxygen to reach the cathode of a lithium/air galvanic… More

Not avaiable

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$118,327.00
Agency:
HHS
Principal Investigator:
Gartner Mark
Abstract:
N/a

Biocompatible Coating for Pediatric Blood Oxygenators - Phase II

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$1,577,494.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Many oxygenators clinically available for pediatric (and adult) extracorporeal membrane oxygenation (ECMO) utilize heparin coatings such as Carmeda BioActive Surface on device surfaces, including the microporous hollow fibers, to improve biocompatibility.… More

Infection resistent coatings for mechanical circulatory support systems (MCSS)

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$157,723.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The high risk of infection posed by the use of paracorporeal and implanted mechanical circulatory support systems (MCSS) continues to create significant clinical complications. In this Phase I proposal, Ension will deve lop and assess the feasibility of a… More

Infection resistant surface for ventricular assist device (VAD) transcutaneous dr

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$1,272,262.00
Agency:
HHS
Principal Investigator:
Patrick T. Cahalan – 412-828-5209
Abstract:
DESCRIPTION (provided by applicant): Infection is a common and frequently very serious complication associated with medical implants. Man-made materials, including those used to fabricate ventricular assist devices (VADs), compromise the body's ability tofight infection in tw ways. First, by… More